Weigh surgical tech costs before buying

Ophthalmology Times argued in a May 2026 commentary that ophthalmic practices should judge new surgical technology by operational results rather than novelty. The publication framed device adoption as a facility-management decision, not an automatic marker of clinical progress. The article said the burden is on a new tool to show a measurable gain before a practice commits capital. In mixed-resource or government settings, it warned, expensive additions can become “furniture” if they do not change how surgery is delivered. ### Why does the article treat a new device as a management decision, not a clinical reflex? The Ophthalmology Times piece said buying surgical technology affects workflow, staffing, room use and cost structure as much as it affects the surgeon’s preference. That framing shifts the question from whether a device is new to whether it solves a defined operational problem. The article’s premise is that a practice should ask what bottleneck, safety issue or training gap the purchase is meant to address before approving it. (ophthalmologytimes.com) A facility-level lens also changes who should be involved. A purchase decision touches surgeons, administrators, nursing staff and trainees because each group absorbs part of the device’s cost or benefit in day-to-day use, the article said. ### What counts as a real benefit big enough to justify the spending? The article set out four tests. A device should improve safety, increase throughput, make training more reproducible, or produce better outcomes in difficult eyes, according to Ophthalmology Times. (ophthalmologytimes.com) Those filters are narrower than a general claim of modernization. They require a practice to identify a measurable effect in the operating room. Safety can mean fewer complications or more control in higher-risk cases. Throughput can mean shorter turnover, more predictable case flow or less wasted theatre time. Training reproducibility matters when a system helps standardize steps across surgeons or trainees rather than depending entirely on individual technique. Difficult-eye outcomes matter when a tool performs better in cases where conventional workflow breaks down. (ophthalmologytimes.com) ### What is the warning for public hospitals and mixed-resource practices? The commentary singled out government and mixed-resource environments because capital budgets are tighter and every purchase competes with other needs. In those settings, the article said, a technology that does not deliver a measurable operational gain risks becoming an expensive object in the theatre rather than a useful instrument. (ophthalmologytimes.com) That warning is practical rather than abstract. A practice may face stronger returns from spending on maintenance, staffing, scheduling systems or core instruments than on a highly marketed platform that does not change outcomes or flow. The article’s argument is that scarcity makes the threshold for adoption clearer, not lower. ### How should a practice screen a proposed purchase before signing off? (ophthalmologytimes.com) A practice can turn the article’s framework into a short checklist. First, define the problem in specific terms: posterior capsule rupture rate, inconsistent trainee performance, slow room turnover, or poor results in complex eyes. Second, ask what number should move if the device works. Third, compare that expected gain with the full cost of purchase, maintenance, disposables and training time. Those steps follow directly from the article’s emphasis on measurable operational benefit. A second screen is comparative. If the same problem can be fixed by protocol changes, better preoperative planning or staff training, the article implies that hardware should not get an automatic pass. The purchase case strengthens only when the device does something process changes cannot do reliably. ### What does this mean for buyers looking at the next device pitch? (ophthalmologytimes.com) The May 2026 commentary leaves practices with a narrower question than whether a technology looks advanced. Ophthalmology Times said the relevant test is whether the device improves a named operational outcome enough to justify its cost in the setting where it will actually be used. The article remains available on the publication’s website for practices reviewing capital purchases and surgical workflow plans.